Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LBX Pharmacy Chain JSCSHSE:603883 -3.00%80 EV-to-FCF is 3.82 as of Jul. 25, 2026, which is 74% below its 10-year median of 14.76. GuruFocus rates SHSE:603883 with a GF Score™ of 80/100 and a GF Value™ of ¥19.25 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 405 Healthcare Providers & Services companies, LBX Pharmacy Chain JSC ranks better than 91.6% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, LBX Pharmacy Chain JSC's Enterprise Value is ¥11,305 Mil.
LBX Pharmacy Chain JSC's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥2,963 Mil. Therefore, LBX Pharmacy Chain JSC's EV-to-FCF for today is 3.82.
The historical rank and industry rank for LBX Pharmacy Chain JSC's EV-to-FCF or its related term are showing as below:
SHSE:603883'
s EV-to-FCF Range Over the Past 10 Years
Min: -611.77 Med: 14.76 Max: 33086.79
Current: 3.8
During the past 13 years, the highest EV-to-FCF of LBX Pharmacy Chain JSC was 33086.79. The lowest was -611.77. And the median was 14.76.
SHSE:603883's EV-to-FCF is ranked better than 91.6% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 17.87
vs SHSE:603883: 3.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LBX Pharmacy Chain JSC's PE Ratio (TTM) for today is calculated as:
LBX Pharmacy Chain JSC's share price for today is ¥11.97.
LBX Pharmacy Chain JSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, LBX Pharmacy Chain JSC's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LBX Pharmacy Chain JSC EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LBX Pharmacy Chain JSC's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where LBX Pharmacy Chain JSC's EV-to-FCF falls into.
LBX Pharmacy Chain JSC's current Enterprise Value is ¥11,305 Mil.
LBX Pharmacy Chain JSC's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,963 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LBX Pharmacy Chain JSC (SHSE:603883) has a EV-to-FCF of 3.82 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on LBX Pharmacy Chain JSC and its competitors. This is 74% below median its historical median of 14.76. According to the industry distribution chart, LBX Pharmacy Chain JSC ranks #34 out of 405 companies in the Healthcare Providers & Services industry, placing it in the top 8.4%.
Is LBX Pharmacy Chain JSC's EV-to-FCF too high?
LBX Pharmacy Chain JSC's current EV-to-FCF of 3.82 is 74% below median its 10-year median of 14.76. The Healthcare Providers & Services industry median EV-to-FCF is 17.87. LBX Pharmacy Chain JSC's value of 3.82 is 78.6% below this industry median. Based on the distribution chart, LBX Pharmacy Chain JSC ranks #34 out of 405 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, LBX Pharmacy Chain JSC has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LBX Pharmacy Chain JSC's EV-to-FCF compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, LBX Pharmacy Chain JSC ranks #34 out of 405 companies for EV-to-FCF. This places LBX Pharmacy Chain JSC in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 17.87. LBX Pharmacy Chain JSC's value of 3.82 is 78.6% below this benchmark. While the company's 10-year median is 14.76 vs. the industry median of 17.87, LBX Pharmacy Chain JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.87, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LBX Pharmacy Chain JSC's current EV-to-FCF of 3.82 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on LBX Pharmacy Chain JSC and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LBX Pharmacy Chain JSC's current EV-to-FCF is 3.82, which is 74% below median its own 10-year median of 14.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LBX Pharmacy Chain JSC stock overvalued right now?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC (SHSE:603883) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥19.25, compared to a current price of ¥11.97 — trading 37.8% below its estimated fair value. The current EV-to-FCF is 3.82, which is 74% below median its 10-year median of 14.76 and 78.6% below the Healthcare Providers & Services industry median of 17.87. LBX Pharmacy Chain JSC's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For LBX Pharmacy Chain JSC (SHSE:603883), the current EV-to-FCF is 3.82 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LBX Pharmacy Chain JSC (SHSE:603883) Overvalued in 2026?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC stock appears to be undervalued.
The current stock price of ¥11.97 is trading 37.8% below its estimated GF Value™ of ¥19.25.
GuruFocus considers LBX Pharmacy Chain JSC to be Significantly Undervalued.
Key valuation signals for SHSE:603883:
EV-to-FCF: 3.82 (74% below median its 10-year median of 14.76)
GF Value™: ¥19.25 vs. price of ¥11.97 (37.8% below fair value)
Industry Position: 78.6% below the Healthcare Providers & Services median (#34 of 405)
No single metric tells the full story. See the SHSE:603883 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.
80GF Score
Get the complete analysis for SHSE:603883
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603883 has been successfully added to your 
